About Vivo Bio Tech Limited
Data last updated: 10 February 2026
Vivo Bio Tech Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 12 February 1987, the company has been in operation for over 39 years.
Registered with ROC Hyderabad under CIN L65993TG1987PLC007163. Listed on BSE: 511509.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹22.19 Cr. It is led by directors including Sri Kalyan Kompella and Satyanarayana Vedula.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2024. Office: 03Rd Floor Ilyas Mohammed Khan Estate #8 – 2 – 672/5 & 6 Road No.1 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the financials filed for FY 2024, the company reported a revenue of ₹45.49 Cr, a decline of 13% compared to the previous year.
The company has a workforce of approximately 5 employees as per the latest available data. Its group structure includes 4 subsidiaries.
The company is associated with 1 brand - Vivo Bio Tech. As per MCA filings, the company has open charges of ₹183.05 Cr and satisfied charges of ₹68.86 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vivobio.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address03Rd Floor Ilyas Mohammed Khan Estate #8 – 2 – 672/5 & 6 Road No.1 Banjara Hills, Hyderabad, Telangana, India – 500034
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Vivo Bio Tech Limited
Vivo Bio Tech Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L65993TG1987PLC007163, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L65993TG1987PLC007163 | Current |
| L65993AP1987PLC007163 | Previous |
| U65993TG1987PLC007163 | Previous |
Associated Brands with Vivo Bio Tech Limited
Vivo Bio Tech Limited operates one associated brand: Vivo Bio Tech. These brands represent Vivo Bio Tech Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| CRO providing drug development, discovery and biologic research services | vivobio.com |
Competitors & Alternatives of Vivo Bio Tech Limited
Brands and companies operating in the same space as Vivo Bio Tech Limited include GenOway, PsychoGenics, PharmaLegacy Laboratories and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
GenOway
|
Provider of transgenic rodent models and customized cell lines for preclinical development | Lyon, France, France | 1999 |
PsychoGenics
|
Preclinical CRO services for CNS and orphan disorders are offered. | Tarrytown, United States, United States | 1999 |
PharmaLegacy Laboratories
|
Preclinical CRO offering in vivo models and services for a wide range of therapeutic areas | Shanghai, China, China | 2008 |
TransCure bioServices
|
Humanized mouse models are developed for preclinical immune drug studies. | Archamps, France, France | 2012 |
InVivo Biosystems
|
Animal models are supplied for in-vivo analytical services. | United States | 2019 |
Explora BioLabs
|
Discovery pharmacology and vivarium services are provided to biotech clients. | San Diego, United States, United States | 2004 |
Noble Life Sciences
|
Preclinical contract research organization offering standard GLP and non-GLP services | Woodbine, United States, United States | 2010 |
ZeClinics
|
Zebrafish models for toxicity studies are developed by ZeClinics CRO. | Barcelona, Spain, Spain | 2013 |
Zebrafish Lab
|
Zebrafish assays are utilized for preclinical and environmental evaluations. | Noain, Spain, Spain | 2015 |
Business Activity of Vivo Bio Tech Limited
Vivo Bio Tech Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Vivo Bio Tech Limited
Vivo Bio Tech Limited is audited by P MURALI & CO., (ICAI peer reviewed, certificate valid till 2028-11-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| P MURALI & CO., (ICAI peer reviewed, certificate valid till 2028-11-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Vivo Bio Tech Limited
Vivo Bio Tech Limited is currently managed by 7 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Vivo Bio Tech Limited FY 2026 filings available
Vivo Bio Tech Limited reported revenue of ₹53.33 Cr (up 14.27% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹53.33 Cr | ₹46.67 Cr | ₹45.45 Cr | ₹52.23 Cr | ₹51.39 Cr | ₹51.78 Cr | ₹55.35 Cr |
| Other Income | ₹44.08 Lakh | ₹4.8 Cr | ₹3.88 Lakh | ₹3.59 Lakh | ₹9.83 Lakh | ₹7.87 Lakh | ₹5.32 Lakh |
| Total Income | ₹53.78 Cr | ₹51.48 Cr | ₹45.49 Cr | ₹52.27 Cr | ₹51.49 Cr | ₹51.85 Cr | ₹55.41 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹8.49 Cr | ₹4.81 Cr | ₹4.65 Cr | ₹4.93 Cr | ₹7.97 Cr | ₹9.91 Cr | ₹10.9 Cr |
| Changes in Inventories | -₹36.19 Lakh | ₹98.35 Lakh | -₹80.13 Lakh | ₹1.84 Cr | ₹3.47 Cr | -₹2.7 Cr | -₹2.34 Cr |
| Employee Benefit Expense | ₹16.49 Cr | ₹12.14 Cr | ₹10.68 Cr | ₹13.52 Cr | ₹9.42 Cr | ₹8.57 Cr | ₹10 Cr |
| Finance Costs | ₹5.85 Cr | ₹7.5 Cr | ₹7.78 Cr | ₹7.65 Cr | ₹3.99 Cr | ₹3.53 Cr | ₹3.1 Cr |
| Depreciation & Amortisation | ₹10.63 Cr | ₹9.02 Cr | ₹9.29 Cr | ₹9.27 Cr | ₹7.45 Cr | ₹5.59 Cr | ₹5.17 Cr |
| Other Expenses | ₹7.27 Cr | ₹8.23 Cr | ₹9.83 Cr | ₹10.43 Cr | ₹14.72 Cr | ₹18.34 Cr | ₹24.33 Cr |
| Total Expenses | ₹48.36 Cr | ₹42.68 Cr | ₹41.43 Cr | ₹47.65 Cr | ₹47.02 Cr | ₹43.23 Cr | ₹51.15 Cr |
| Profit Before Exceptional Items & Tax | ₹5.41 Cr | ₹8.79 Cr | ₹4.06 Cr | ₹4.62 Cr | ₹4.47 Cr | ₹8.62 Cr | ₹4.25 Cr |
| Exceptional Items | -₹60.45 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.81 Cr | ₹8.79 Cr | ₹4.06 Cr | ₹4.62 Cr | ₹4.47 Cr | ₹8.62 Cr | ₹4.25 Cr |
| Total Tax Expense | ₹6.52 Cr | ₹1.51 Cr | ₹1.53 Cr | ₹1.97 Cr | ₹2.27 Cr | ₹2.94 Cr | -₹18.82 Lakh |
| Net Profit | -₹1.71 Cr | ₹7.28 Cr | ₹2.53 Cr | ₹2.65 Cr | ₹2.2 Cr | ₹5.68 Cr | ₹4.44 Cr |
| attributable to Owners | - | - | ₹2.53 Cr | ₹2.65 Cr | ₹0 | ₹5.68 Cr | ₹4.44 Cr |
| attributable to NCI | - | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹4.44 Cr |
| Total Comprehensive Income | -₹1.71 Cr | ₹7.28 Cr | ₹2.53 Cr | ₹2.65 Cr | ₹2.2 Cr | ₹5.68 Cr | ₹8.88 Cr |
| EBITDA (computed) | ₹21.89 Cr | ₹25.31 Cr | ₹21.13 Cr | ₹21.54 Cr | ₹15.91 Cr | ₹17.74 Cr | ₹12.52 Cr |
| Basic EPS | ₹-0.82 | ₹4.76 | ₹1.70 | ₹1.78 | ₹1.56 | ₹4.23 | ₹3.45 |
| Diluted EPS | ₹-0.82 | ₹4.76 | ₹1.51 | ₹1.78 | ₹1.56 | ₹4.20 | ₹3.45 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹178.43 Cr | ₹143.23 Cr | ₹137.13 Cr | ₹123.03 Cr | ₹122.49 Cr | ₹79.52 Cr | ₹62.14 Cr |
| Non-current Assets | ₹150.02 Cr | ₹101.29 Cr | ₹89.9 Cr | ₹91.24 Cr | ₹96.45 Cr | ₹52.44 Cr | ₹35.22 Cr |
| Current Assets | ₹28.42 Cr | ₹41.94 Cr | ₹47.23 Cr | ₹31.79 Cr | ₹26.03 Cr | ₹27.09 Cr | ₹26.92 Cr |
| Property, Plant & Equipment | ₹71.8 Cr | ₹64.38 Cr | ₹72.25 Cr | ₹78.07 Cr | ₹81.55 Cr | ₹40.71 Cr | ₹28.61 Cr |
| Inventories | ₹8.15 Cr | ₹7.79 Cr | ₹8.77 Cr | ₹7.97 Cr | ₹9.81 Cr | ₹13.28 Cr | ₹10.58 Cr |
| Trade Receivables | ₹11.75 Cr | ₹11.25 Cr | ₹11.8 Cr | ₹12.38 Cr | ₹12.02 Cr | ₹7.29 Cr | ₹10.48 Cr |
| Cash & Equivalents | ₹1.44 Cr | ₹1.28 Cr | ₹1.39 Cr | ₹1.37 Cr | ₹1.71 Cr | ₹1.17 Cr | ₹1.03 Cr |
| Equity (Net Worth) | ₹93.16 Cr | ₹77.9 Cr | ₹54.4 Cr | ₹51.87 Cr | ₹45.95 Cr | ₹42.53 Cr | ₹33.02 Cr |
| Equity Share Capital | ₹22.19 Cr | ₹17.16 Cr | ₹14.9 Cr | ₹14.9 Cr | ₹14.26 Cr | ₹13.42 Cr | ₹12.89 Cr |
| Borrowings (Non-current) | ₹46.61 Cr | ₹34.94 Cr | ₹41.79 Cr | ₹43.09 Cr | ₹50.08 Cr | ₹14.65 Cr | ₹9.69 Cr |
| Borrowings (Current) | ₹20.77 Cr | ₹19.09 Cr | ₹31.28 Cr | ₹19.3 Cr | ₹17.36 Cr | ₹16.31 Cr | ₹14.67 Cr |
| Total Debt (computed) | ₹67.38 Cr | ₹54.03 Cr | ₹73.06 Cr | ₹62.4 Cr | ₹67.44 Cr | ₹30.96 Cr | ₹24.36 Cr |
| Current Liabilities | ₹30.23 Cr | ₹27.84 Cr | ₹37.91 Cr | ₹24.97 Cr | ₹24.36 Cr | ₹21.84 Cr | ₹20.56 Cr |
| Total Liabilities | ₹85.27 Cr | ₹65.33 Cr | ₹82.73 Cr | ₹71.16 Cr | ₹76.54 Cr | ₹37 Cr | ₹29.12 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹34.93 Cr | ₹11.83 Cr | ₹15.52 Cr | ₹7.37 Cr | ₹15.01 Cr |
| Investing Cash Flow | -₹59.35 Cr | -₹15.84 Cr | -₹7.95 Cr | -₹4 Cr | -₹51.11 Cr |
| Financing Cash Flow | ₹24.57 Cr | ₹3.9 Cr | -₹7.56 Cr | -₹3.71 Cr | ₹36.65 Cr |
| Capital Expenditure | ₹37.44 Cr | ₹22.5 Lakh | ₹7.95 Cr | ₹4 Cr | ₹51.11 Cr |
| Free Cash Flow (computed) | -₹2.51 Cr | ₹11.6 Cr | ₹7.57 Cr | ₹3.37 Cr | -₹36.1 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹15.48 Lakh | -₹10.9 Lakh | ₹1.48 Lakh | -₹33.88 Lakh | ₹55.23 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹14.2 Cr | ₹13.51 Cr | ₹13.11 Cr | ₹12.51 Cr | ₹12.29 Cr | ₹12.21 Cr | ₹12.04 Cr | ₹10.13 Cr |
| Other Income | ₹3.04 Lakh | ₹13.86 Lakh | ₹13.39 Lakh | ₹13.78 Lakh | ₹15.31 Lakh | ₹85,000 | ₹4.63 Cr | ₹1.23 Lakh |
| Total Income | ₹14.23 Cr | ₹13.65 Cr | ₹13.24 Cr | ₹12.65 Cr | ₹12.44 Cr | ₹12.22 Cr | ₹16.67 Cr | ₹10.15 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹2.77 Cr | ₹2.98 Cr | ₹1.11 Cr | ₹1.63 Cr | ₹1.56 Cr | ₹83.35 Lakh | ₹90.57 Lakh | ₹1.51 Cr |
| Changes in Inventories | -₹40.26 Lakh | -₹81.83 Lakh | ₹98.76 Lakh | -₹12.86 Lakh | -₹79.16 Lakh | ₹1.03 Cr | ₹57.06 Lakh | ₹17.21 Lakh |
| Employee Benefit Expense | ₹4.88 Cr | ₹4.33 Cr | ₹4.08 Cr | ₹3.2 Cr | ₹3.14 Cr | ₹3.22 Cr | ₹3.44 Cr | ₹2.34 Cr |
| Finance Costs | ₹1.48 Cr | ₹1.4 Cr | ₹1.47 Cr | ₹1.5 Cr | ₹1.68 Cr | ₹1.84 Cr | ₹2.06 Cr | ₹1.92 Cr |
| Depreciation & Amortisation | ₹2.75 Cr | ₹2.66 Cr | ₹2.57 Cr | ₹2.64 Cr | ₹2.25 Cr | ₹2.25 Cr | ₹2.29 Cr | ₹2.23 Cr |
| Other Expenses | ₹1.9 Cr | ₹1.53 Cr | ₹1.52 Cr | ₹2.31 Cr | ₹3.36 Cr | ₹1.59 Cr | ₹1.52 Cr | ₹1.75 Cr |
| Total Expenses | ₹13.38 Cr | ₹12.08 Cr | ₹11.73 Cr | ₹11.17 Cr | ₹11.2 Cr | ₹10.76 Cr | ₹10.8 Cr | ₹9.92 Cr |
| Profit Before Exceptional Items & Tax | ₹85.55 Lakh | ₹1.57 Cr | ₹1.51 Cr | ₹1.48 Cr | ₹1.24 Cr | ₹1.46 Cr | ₹5.87 Cr | ₹22.24 Lakh |
| Exceptional Items | -₹60.45 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹25.1 Lakh | ₹1.57 Cr | ₹1.51 Cr | ₹1.48 Cr | ₹1.24 Cr | ₹1.46 Cr | ₹5.87 Cr | ₹22.24 Lakh |
| Total Tax Expense | ₹5.41 Cr | ₹32.16 Lakh | ₹64.05 Lakh | ₹14.28 Lakh | ₹17.87 Lakh | ₹64.19 Lakh | ₹63.35 Lakh | ₹5.62 Lakh |
| Net Profit | -₹5.16 Cr | ₹1.25 Cr | ₹86.86 Lakh | ₹1.34 Cr | ₹1.06 Cr | ₹82 Lakh | ₹5.23 Cr | ₹16.62 Lakh |
| attributable to Owners | - | - | - | ₹0 | - | - | ₹0 | ₹16.62 Lakh |
| attributable to NCI | - | - | - | ₹0 | - | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹5.16 Cr | ₹1.25 Cr | ₹86.86 Lakh | ₹1.34 Cr | ₹1.06 Cr | ₹82 Lakh | ₹5.23 Cr | ₹16.62 Lakh |
| EBITDA (computed) | ₹5.08 Cr | ₹5.63 Cr | ₹5.55 Cr | ₹5.63 Cr | ₹5.17 Cr | ₹5.55 Cr | ₹10.22 Cr | ₹4.38 Cr |
| Basic EPS | ₹-2.52 | ₹0.56 | ₹0.45 | ₹0.74 | ₹0.69 | ₹0.55 | ₹3.51 | ₹0.11 |
| Diluted EPS | ₹-2.52 | ₹0.56 | ₹0.45 | ₹0.74 | ₹0.69 | ₹0.55 | ₹3.51 | ₹0.11 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹52.57 Cr | ₹46.67 Cr | ₹44.88 Cr | ₹51.62 Cr | ₹51.39 Cr | ₹51.78 Cr | ₹55.35 Cr |
| Other Income | ₹44.08 Lakh | ₹4.8 Cr | ₹3.88 Lakh | ₹3.59 Lakh | ₹9.21 Lakh | ₹7.87 Lakh | ₹5.32 Lakh |
| Total Income | ₹53.01 Cr | ₹51.48 Cr | ₹44.92 Cr | ₹51.66 Cr | ₹51.48 Cr | ₹51.85 Cr | ₹55.41 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹8.49 Cr | ₹4.81 Cr | ₹4.65 Cr | ₹4.93 Cr | ₹7.97 Cr | ₹9.91 Cr | ₹10.9 Cr |
| Changes in Inventories | -₹36.19 Lakh | ₹98.35 Lakh | -₹80.13 Lakh | ₹1.84 Cr | ₹3.47 Cr | -₹2.7 Cr | -₹2.34 Cr |
| Employee Benefit Expense | ₹15.95 Cr | ₹11.86 Cr | ₹10.13 Cr | ₹13.15 Cr | ₹9.42 Cr | ₹8.57 Cr | ₹10 Cr |
| Finance Costs | ₹5.85 Cr | ₹7.5 Cr | ₹7.78 Cr | ₹7.65 Cr | ₹3.99 Cr | ₹3.53 Cr | ₹3.1 Cr |
| Depreciation & Amortisation | ₹10.63 Cr | ₹9.02 Cr | ₹9.29 Cr | ₹9.27 Cr | ₹7.44 Cr | ₹5.59 Cr | ₹5.17 Cr |
| Other Expenses | ₹7.27 Cr | ₹8.22 Cr | ₹9.81 Cr | ₹10.22 Cr | ₹14.72 Cr | ₹18.33 Cr | ₹24.32 Cr |
| Total Expenses | ₹47.82 Cr | ₹42.4 Cr | ₹40.86 Cr | ₹47.05 Cr | ₹47.01 Cr | ₹43.23 Cr | ₹51.15 Cr |
| Profit Before Exceptional Items & Tax | ₹5.19 Cr | ₹9.08 Cr | ₹4.05 Cr | ₹4.61 Cr | ₹4.47 Cr | ₹8.62 Cr | ₹4.26 Cr |
| Exceptional Items | -₹60.45 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.58 Cr | ₹9.08 Cr | ₹4.05 Cr | ₹4.61 Cr | ₹4.47 Cr | ₹8.62 Cr | ₹4.26 Cr |
| Total Tax Expense | ₹6.52 Cr | ₹1.51 Cr | ₹1.53 Cr | ₹1.97 Cr | ₹2.27 Cr | ₹2.94 Cr | -₹18.82 Lakh |
| Net Profit | -₹1.94 Cr | ₹7.57 Cr | ₹2.52 Cr | ₹2.63 Cr | ₹2.2 Cr | ₹5.68 Cr | ₹4.44 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.94 Cr | ₹7.57 Cr | ₹2.52 Cr | ₹2.63 Cr | ₹2.2 Cr | ₹5.68 Cr | ₹4.44 Cr |
| EBITDA (computed) | ₹21.66 Cr | ₹25.6 Cr | ₹21.12 Cr | ₹21.52 Cr | ₹15.91 Cr | ₹17.74 Cr | ₹12.53 Cr |
| Basic EPS | ₹-0.93 | ₹4.95 | ₹1.69 | ₹1.77 | ₹1.56 | ₹4.24 | ₹3.45 |
| Diluted EPS | ₹-0.93 | ₹4.95 | ₹1.51 | ₹1.77 | ₹1.56 | ₹4.20 | ₹3.45 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹174.86 Cr | ₹141.29 Cr | ₹134.8 Cr | ₹120.81 Cr | ₹120.3 Cr | ₹77.31 Cr | ₹59.87 Cr |
| Non-current Assets | ₹146.7 Cr | ₹97.97 Cr | ₹86.58 Cr | ₹87.92 Cr | ₹93.12 Cr | ₹49.1 Cr | ₹31.88 Cr |
| Current Assets | ₹28.17 Cr | ₹43.31 Cr | ₹48.22 Cr | ₹32.88 Cr | ₹27.18 Cr | ₹28.21 Cr | ₹27.99 Cr |
| Property, Plant & Equipment | ₹68.44 Cr | ₹61.02 Cr | ₹68.89 Cr | ₹74.71 Cr | ₹78.19 Cr | ₹37.35 Cr | ₹25.25 Cr |
| Inventories | ₹8.15 Cr | ₹7.79 Cr | ₹8.77 Cr | ₹7.97 Cr | ₹9.81 Cr | ₹13.28 Cr | ₹10.58 Cr |
| Trade Receivables | ₹11.75 Cr | ₹11.21 Cr | ₹11.37 Cr | ₹12.38 Cr | ₹12.02 Cr | ₹7.29 Cr | ₹10.48 Cr |
| Cash & Equivalents | ₹1.3 Cr | ₹1.21 Cr | ₹1.32 Cr | ₹99.37 Lakh | ₹1.47 Cr | ₹1.1 Cr | ₹99.06 Lakh |
| Equity (Net Worth) | ₹93.22 Cr | ₹78.19 Cr | ₹54.4 Cr | ₹51.87 Cr | ₹47.14 Cr | ₹42.54 Cr | ₹33.04 Cr |
| Equity Share Capital | ₹22.19 Cr | ₹17.16 Cr | ₹14.9 Cr | ₹14.9 Cr | ₹14.26 Cr | ₹13.42 Cr | ₹12.89 Cr |
| Borrowings (Non-current) | ₹43.15 Cr | ₹32.71 Cr | ₹39.56 Cr | ₹40.87 Cr | ₹47.88 Cr | ₹12.42 Cr | ₹7.41 Cr |
| Borrowings (Current) | ₹20.77 Cr | ₹19.09 Cr | ₹31.28 Cr | ₹19.3 Cr | ₹17.36 Cr | ₹16.31 Cr | ₹14.67 Cr |
| Total Debt (computed) | ₹63.92 Cr | ₹51.8 Cr | ₹70.84 Cr | ₹60.17 Cr | ₹65.24 Cr | ₹28.73 Cr | ₹22.09 Cr |
| Current Liabilities | ₹30.07 Cr | ₹27.84 Cr | ₹37.81 Cr | ₹24.97 Cr | ₹23.18 Cr | ₹21.83 Cr | ₹20.56 Cr |
| Total Liabilities | ₹81.65 Cr | ₹63.1 Cr | ₹80.4 Cr | ₹68.93 Cr | ₹73.15 Cr | ₹34.77 Cr | ₹26.84 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹36.11 Cr | ₹11.83 Cr | ₹15.83 Cr | ₹8.44 Cr | ₹13.62 Cr |
| Investing Cash Flow | -₹59.35 Cr | -₹15.84 Cr | -₹7.95 Cr | -₹4 Cr | -₹51.11 Cr |
| Financing Cash Flow | ₹23.34 Cr | ₹3.9 Cr | -₹7.56 Cr | -₹4.92 Cr | ₹37.85 Cr |
| Capital Expenditure | ₹37.44 Cr | ₹22.5 Lakh | ₹7.95 Cr | ₹4 Cr | ₹51.11 Cr |
| Free Cash Flow (computed) | -₹1.33 Cr | ₹11.61 Cr | ₹7.88 Cr | ₹4.44 Cr | -₹37.49 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹9.4 Lakh | -₹10.71 Lakh | ₹32.23 Lakh | -₹47.26 Lakh | ₹36.39 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹13.77 Cr | ₹13.37 Cr | ₹13.02 Cr | ₹12.42 Cr | ₹12.29 Cr | ₹12.21 Cr | ₹12.04 Cr | ₹10.13 Cr |
| Other Income | ₹3.04 Lakh | ₹13.86 Lakh | ₹13.39 Lakh | ₹13.78 Lakh | ₹15.31 Lakh | ₹85,000 | ₹4.63 Cr | ₹1.23 Lakh |
| Total Income | ₹13.8 Cr | ₹13.5 Cr | ₹13.15 Cr | ₹12.56 Cr | ₹12.44 Cr | ₹12.22 Cr | ₹16.67 Cr | ₹10.15 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹2.77 Cr | ₹2.98 Cr | ₹1.11 Cr | ₹1.63 Cr | ₹1.56 Cr | ₹83.35 Lakh | ₹90.57 Lakh | ₹1.51 Cr |
| Changes in Inventories | -₹40.26 Lakh | -₹81.83 Lakh | ₹98.76 Lakh | -₹12.86 Lakh | -₹79.16 Lakh | ₹1.03 Cr | ₹57.06 Lakh | ₹17.21 Lakh |
| Employee Benefit Expense | ₹4.72 Cr | ₹4.17 Cr | ₹3.99 Cr | ₹3.07 Cr | ₹3.02 Cr | ₹3.14 Cr | ₹3.36 Cr | ₹2.33 Cr |
| Finance Costs | ₹1.48 Cr | ₹1.4 Cr | ₹1.47 Cr | ₹1.5 Cr | ₹1.68 Cr | ₹1.84 Cr | ₹2.06 Cr | ₹1.92 Cr |
| Depreciation & Amortisation | ₹2.75 Cr | ₹2.66 Cr | ₹2.57 Cr | ₹2.64 Cr | ₹2.25 Cr | ₹2.25 Cr | ₹2.29 Cr | ₹2.23 Cr |
| Other Expenses | ₹1.9 Cr | ₹1.53 Cr | ₹1.52 Cr | ₹2.31 Cr | ₹3.36 Cr | ₹1.59 Cr | ₹1.52 Cr | ₹1.75 Cr |
| Total Expenses | ₹13.22 Cr | ₹11.92 Cr | ₹11.64 Cr | ₹11.04 Cr | ₹11.08 Cr | ₹10.68 Cr | ₹10.72 Cr | ₹9.91 Cr |
| Profit Before Exceptional Items & Tax | ₹58.13 Lakh | ₹1.58 Cr | ₹1.51 Cr | ₹1.52 Cr | ₹1.36 Cr | ₹1.54 Cr | ₹5.95 Cr | ₹23.4 Lakh |
| Exceptional Items | -₹60.45 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹2.32 Lakh | ₹1.58 Cr | ₹1.51 Cr | ₹1.52 Cr | ₹1.36 Cr | ₹1.54 Cr | ₹5.95 Cr | ₹23.4 Lakh |
| Total Tax Expense | ₹5.41 Cr | ₹32.16 Lakh | ₹64.05 Lakh | ₹14.28 Lakh | ₹17.87 Lakh | ₹64.19 Lakh | ₹63.35 Lakh | ₹5.62 Lakh |
| Net Profit | -₹5.44 Cr | ₹1.26 Cr | ₹86.92 Lakh | ₹1.37 Cr | ₹1.19 Cr | ₹89.43 Lakh | ₹5.31 Cr | ₹17.78 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹5.44 Cr | ₹1.26 Cr | ₹86.92 Lakh | ₹1.37 Cr | ₹1.19 Cr | ₹89.43 Lakh | ₹5.31 Cr | ₹17.78 Lakh |
| EBITDA (computed) | ₹4.81 Cr | ₹5.64 Cr | ₹5.55 Cr | ₹5.66 Cr | ₹5.29 Cr | ₹5.62 Cr | ₹10.3 Cr | ₹4.39 Cr |
| Basic EPS | ₹-2.65 | ₹0.57 | ₹0.45 | ₹0.76 | ₹0.78 | ₹0.60 | ₹3.56 | ₹0.12 |
| Diluted EPS | ₹-2.65 | ₹0.57 | ₹0.45 | ₹0.76 | ₹0.78 | ₹0.60 | ₹3.56 | ₹0.12 |
Shareholding Pattern of Vivo Bio Tech Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 35.43%, retail and other public shareholders hold 64.57% of Vivo Bio Tech Limited. The company had 21,427 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 35.43% | 35.16% | 35.16% | 39.06% | 40.85% | 38.88% |
| Public | 64.57% | 64.84% | 64.84% | 60.94% | 59.15% | 61.12% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 35.43% | 40.85% | 42.08% |
| Public | 64.57% | 59.15% | 57.92% |
| Promoter change (YoY, %pts) | -5.42 | -1.23 | - |
Group Structure of Vivo Bio Tech Limited
Vivo Bio Tech Limited has 4 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Vivo Bio Tech Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Vivobio Discovery Services Private Limited | U24232TG2009PTC065604 | - |
| Vivobio Labs Private Limited | U73100TG2009PTC065603 | - |
| Surlogic Life Consultancy Private Limited | U74999TG2010PTC068943 | - |
| Vivobio Consulting Services Private Limited | U74999TG2018PTC125356 | - |
Showing major subsidiaries. Total: 4.
Charges & Borrowings of Vivo Bio Tech Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Nov 2025 | Others | ₹7.57 Cr | Open |
| 25 Sep 2025 | The South Indian Bank Limited | ₹52 Lakh | Open |
| 25 Sep 2025 | Others | ₹3.65 Cr | Open |
| 24 Apr 2025 | Canara Bank | ₹9.2 Lakh | Open |
| 17 Oct 2023 | Others | ₹18 Cr | Open |
Total charge records: 28 View all charges
Employees and EPFO Compliance at Vivo Bio Tech Limited
Vivo Bio Tech Limited has a workforce of 5 employees as of Apr 06, 2024.
Employee Count & EPFO Data of Vivo Bio Tech Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Vivo Bio Tech Limited
GSTIN & GST Filing Data of Vivo Bio Tech Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Vivo Bio Tech Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Vivo Bio Tech Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Vivo Bio Tech Limited
MSME Payment Delays by Vivo Bio Tech Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Vivo Bio Tech Limited
Subsidiaries & Group Companies of Vivo Bio Tech Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Vivo Bio Tech Limited with ownership details.
MCA Filings & Documents of Vivo Bio Tech Limited
MCA Filings & Documents of Vivo Bio Tech Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Vivo Bio Tech Limited
Recent News on Vivo Bio Tech Limited
Frequently Asked Questions about Vivo Bio Tech Limited
Vivo Bio Tech Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 12 February 1987 (39+ years old) and is registered under CIN L65993TG1987PLC007163. Listed on BSE: 511509. The company has 5 employees.
Vivo Bio Tech Limited reported revenue of ₹45.49 Cr for FY 2024 (down 13.00% YoY).
The current directors of Vivo Bio Tech Limited are:
- Sri Kalyan Kompella
- Satyanarayana Vedula
- Vaishnavi Kiran Ayinampudi
- Priya Rajender Goda
- Shyam Sunder Tipparaju
- Kalyan Ram Mangipudi
- Sankaranarayanan Alangudi
The primary industry of Vivo Bio Tech Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes. Vivo Bio Tech Limited is listed on BSE with code 511509.
Vivo Bio Tech Limited can be reached at the registered office: 03Rd Floor Ilyas Mohammed Khan Estate #8 – 2 – 6725 & 6 Road No.1 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website vivobio.com.